A shared accretion instability for black holes and neutron stars

Accretion disks around compact objects are expected to enter an unstable phase at high luminosity1. One instability may occur when the radiation pressure generated by accretion modifies the disk viscosity, resulting in the cyclic depletion and refilling of the inner disk on short timescales2. Such a scenario, however, has only been quantitatively verified for a single stellar-mass black hole3-5. Although there are hints of these cycles in a few isolated cases6-10, their apparent absence in the variable emission of most bright accreting neutron stars and black holes has been a continuing puzzle11. Here we report the presence of the same multiwavelength instability around an accreting neutron star. Moreover, we show that the variability across the electromagnetic spectrum-from radio to X-ray-of both black holes and neutron stars at high accretion rates can be explained consistently if the accretion disks are unstable, producing relativistic ejections during transitions that deplete or refill the inner disk. Such a new association allows us to identify the main physical components responsible for the fast multiwavelength variability of highly accreting compact objects.

X-ray quasi-periodic eruptions from two previously quiescent galaxies

Quasi-periodic eruptions (QPEs) are very-high-amplitude bursts of X-ray radiation recurring every few hours and originating near the central supermassive black holes of galactic nuclei^1,2. It is currently unknown what triggers these events, how long they last and how they are connected to the physical properties of the inner accretion flows. Previously, only two such sources were known, found either serendipitously or in archival data^1,2, with emission lines in their optical spectra classifying their nuclei as hosting an actively accreting supermassive black hole^3,4. Here we report observations of QPEs in two further galaxies, obtained with a blind and systematic search of half of the X-ray sky. The optical spectra of these galaxies show no signature of black hole activity, indicating that a pre-existing accretion flow that is typical of active galactic nuclei is not required to trigger these events. Indeed, the periods, amplitudes and profiles of the QPEs reported here are inconsistent with current models that invoke radiation-pressure-driven instabilities in the accretion disk^5–9. Instead, QPEs might be driven by an orbiting compact object. Furthermore, their observed properties require the mass of the secondary object to be much smaller than that of the main body¹⁰, and future X-ray observations may constrain possible changes in their period owing to orbital evolution. This model could make QPEs a viable candidate for the electromagnetic counterparts of so-called extreme-mass-ratio inspirals^11–13, with considerable implications for multi-messenger astrophysics and cosmology^14,15.

X-ray quasi-periodic eruptions are detected from two previously inactive galaxies, with observations suggesting that the very-high-amplitude X-ray bursts may arise from an orbiting compact object.

Benzyl amide-ketoacid inhibitors of HIV-integrase

Integrase is one of three enzymes expressed by HIV and represents a validated target for therapy. Previous reports have demonstrated that the diketoacid-based chemotype is a useful starting point for the design of inhibitors of this enzyme. In this study, one of the ketone groups is replaced by a benzylamide resulting in a new potent chemotype. A preliminary SAR study is carried out to investigate the substitution requirements on the phenyl ring and methylene group of the benzylamide.

Exploration of the diketoacid integrase inhibitor chemotype leading to the discovery of the anilide-ketoacids chemotype

Integrase is one of three enzymes expressed by HIV and represents a validated target for therapy. A previous study of the diketoacid-based chemotype suggested that there are two aryl-binding domains on integrase. In this study, modifications to the indole-based diketoacid chemotype are explored. It is demonstrated that the indole group can be replaced with secondary but not tertiary (e.g., N-methyl) aniline-based amides without sacrificing in vitro inhibitory activity. The difference in activity between the secondary and tertiary amides is most likely due to the opposite conformational preferences of the amide bonds, s-trans for the secondary-amide and s-cis for the tertiary-amide. However, it was found that the conformational preference of the tertiary amide can be reversed by incorporating the amide nitrogen atom into an indoline heterocycle, resulting in very potent integrase inhibitors.

Triketoacid inhibitors of HIV-integrase: A new chemotype useful for probing the integrase pharmacophore

Integrase is one of three enzymes expressed by HIV and represents a validated target for therapy. This study reports on the discovery of a new triketoacid-based chemotype that selectively inhibits the strand transfer reaction of HIV-integrase. SAR studies showed that the template binds to integrase in a manner similar to the diketoacid-based inhibitors. Moreover, comparison of the new chemotype to two different diketoacid templates led us to propose two aryl-binding domains in the inhibitor binding site. This information was used to design a new diketoacid template with improved activity against the enzyme.

192 THE USE OF FIXED-TIME TECHNIQUES AND eCG TO SYNCHRONIZE RECIPIENTS for FROZEN - THAWED BOVINE IVF EMBRYOS

Two experiments were designed to investigate the use of eCG in a fixed-time embryo transfer (FTET) protocol for Chinese Yellow crossbred recipients receiving in vitro-produced (IVP) bovine embryos. In Experiment 1, cows were observed for spontaneous estrus (Group 1) or following 500 �g cloprostenol (PGF; Schering-Plough Animal Health, Montreal, Quebec, Canada; Group 2) with nonsurgical embryo transfer 7.5 or 8.0 days later. Cows in Groups 3, 4, and 5 were treated with a CIDR insert (Bioniche Animal Health, Beijing, China), 2 mg estradiol benzoate (EB), and 50 mg progesterone (Sigma-Aldrich, Canada) i.m. on Day 0, PGF on Day 5, CIDR removal on Day 7, and 1 mg EB i.m. 24 h later with nonsurgical transfer of Holstein IVP embryos 8.5 days later, without estrus detection. In addition, cows in Group 3 received no further treatment, whereas cows in Group 4 received 400 IU eCG i.m. (Pregnecol; Bioniche) on Day 5, and cows in Group 5 received eCG on Day 7. Holstein embryos were produced utilizing slaughterhouse ovaries and standard IVF procedures. Expanded blastocysts of quality grade 1 (IETS) were cryopreserved in 10% ethylene glycol and 20% fetal bovine serum using standard procedures. Straws were thawed in a 30�C water bath, and embryos were expelled directly into holding medium and evaluated prior to nonsurgical transfer (NT) ipsilateral to the corpus luteum (CL). Pregnancy was diagnosed ultrasonically 30 d later. Although pregnancy rates, based on numbers of recipients synchronized, numerically favored the administration of eCG on Day 5, there were no significant differences (P = 0.40) among groups (Group 1: 15.4%, n = 52; Group 2: 20.0%, n = 50; Group 3: 19.2%, n = 99; Group 4: 28.1%, n = 96; Group 5: 21.3%, n = 75). In Experiment 2, Chinese Yellow crossbred cattle were synchronized with a CIDR insert plus estradiol and progesterone on Day 0, PGF on Day 5, CIDR removal on Day 7 and estradiol on Day 8, and were randomly assigned to received no further treatment (Group 1; n = 400) or an injection of 400 IU eCG on Day 5 (Group 2; n = 391). Recipients with a detectable CL received a frozen-thawed IVP Holstein embryo by NT 8.5 days after the second injection of estradiol without estrus detection, as in the first experiment. Pregnancy diagnosis was done ultrasonically 30 days later. Although CL size, cow age, and embryo quality, prior to transfer, were recorded, no effects on pregnancy rates were demonstrated (P = 0.30). Pregnancy rates, based on recipients receiving embryos, did not differ (P = 0.5) between groups (Group 1: 21.4%, n = 154; Group 2: 24.5%, n = 290). Overall pregnancy rates (based on the total number of recipients synchronized) were significantly higher (P < 0.001) in Group 2 (eCG; 18.2%) than in Group 1 (no eCG; 8.3%), because of the significantly higher (P < 0.03) percentage of recipients used following treatment with eCG (74.2% vs. 38.5%). Results indicate that the administration of eCG on Day 5 of an 8-d synchronization protocol for FTET of frozen-thawed bovine IVP embryos will improve pregnancy rates in beef recipients, especially those of marginal quality.

BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models

Cytosolic phospholipase A2 (cPLA2) catalyzes the selective release of arachidonic acid from the sn-2 position of phospholipids and is believed to play a key cellular role in the generation of arachidonic acid. BMS-229724 (4-[4-[2-[2-[bis(4-chlorophenyl)methoxy]ethyl-sulfonyl]ethoxy]phenyl]-1,1,1-trifluoro-2-butanone) was found to be a selective inhibitor of cPLA2 (IC50 = 2.8 microM) in that it did not inhibit secreted phospholipase A2 in vitro, nor phospholipase C and phospholipase D in cells. The compound was active in inhibiting arachidonate and eicosanoid production in U937 cells, neutrophils, platelets, monocytes, and mast cells. With a synthetic covesicle substrate system, the dose-dependent inhibition could be defined by kinetic equations describing competitive inhibition at the lipid/water interface. The apparent equilibrium dissociation constant for the inhibitor bound to the enzyme at the interface (K(I)*(app)) was determined to be 1. 10(-5) mol% versus an apparent dissociation constant for the arachidonate-containing phospholipid of 0.35 mol%. The unit of concentration in the interface is mole fraction (or mol%), which is related to the surface concentration of substrate, rather than bulk concentration that has units of molarity. Thus, BMS-229724 represents a novel inhibitor of cPLA2, which partitions into the phospholipid bilayer and competes with phospholipid substrate for the active site. This potent inhibition of the enzyme translated into anti-inflammatory activity when applied topically (5%, w/v) to a phorbol ester-induced chronic inflammation model in mouse ears, inhibiting edema and neutrophil infiltration, as well as prostaglandin and leukotriene levels in the skin. In hairless guinea pigs, BMS-229724 was active orally (10 mg/kg) in a UVB-induced skin erythema model in hairless guinea pigs.

Sulfated galactocerebrosides as potential antiinflammatory agents

Native sulfatides, as well as many sulfated glycolipids, have been shown to avidly bind to the selectin receptors. In vivo, native sulfatides significantly block activity in selectin-dependent inflammatory responses. The fact that nonsulfated galactocerebrosides did not inhibit selectin-mediated adhesion identified a critical role for the anionic sulfate residue. We therefore initiated a program to evaluate the activity of position isomers. This study showed a binding selectivity for the positions 2 and 3 of the sulfate group on the carbohydrate ring as well as enhanced activity for the disulfated analogs. Furthermore, it was discovered that the attachment of lipophilic substituents on the carbohydrate ring was tolerated, consistent with the presence of a lipophilic pocket in the binding activity. This resulted in compounds with a 6-fold increased potency.